I do not know about the rest of you here.......whether you are related to Rob or not but I suspect somebody has a connection in some form or another...but for me this ceo is worthless in creating a transparent process for all shareholders to see....trademark for their one main product granted to Orpheus Medica on Sept.04....they then terminated their agreement with OrpheusMedica 'after' shelling out cash and shares to them.....terminated? For what legitimate reason did they terminate this agreement? If Orpheus Medica had all these connections and experience why was it necessary to terminate them and form a new expensive JV with no track record in any health approval process????!
Do you see why the the words...sleaze factor....should not be shoved under the rug. glta
Toronto, Ontario--(Newsfile Corp. - August 27, 2020) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), a progressive medical device technology company, is pleased to announce that it has signed a co-development definitive agreement with Orpheus Medica Inc. ("Orpheus") or (Therma & Orpheus, the "Parties"). This agreement will allow Therma access to Orpheus' novel biological platform and the joint development of a rapid saliva test for the screening and detection of the virus (SARS-CoV-2) causing COVID-19.
Under this agreement, Therma will provide funding for the project in phases ("Phase" or "Phases") as certain developmental milestones are achieved, Therma will commit up to $300,000 for Phase 1 which will focus on the identification of anti-COVID-19 poly-peptides to be utilized in the test prototype development stage. Therma and Orpheus expect Phase 1 to take approximately 45 days to complete. Therma and Orpheus have identified several 3rd party providers to assist with the Phase 1 development path.
During Phase 2, Therma's and Orpheus' partnership with various clinical institutions will focus on clinical validation of the test prototype in up to 250 clinical samples. After Phase 2, Therma can decide to advance to Phase 3 only upon success with Phases 1 and 2. Phase 3 will include regulatory enabling studies where the Parties expect to apply for EUA approvals during Phase 3 including commercialization activities.
Upon approval by regulatory bodies of CoviSafe™, Therma and Orpheus expect to market its rapid test for use by education systems, businesses of all types, public events and other venues, sporting events or activities where a COVID-19 test is required and useful.
As stated in the Therma press release on August 20, 2020, CoviSafe™ is intended to have unique features such as high accuracy, sensitivity, and specificity while delivering results in less than 20 minutes. CoviSafe™ screens and directly detects the virus rather than its genetic material in saliva or as needed in other biological samples. It can be tested anywhere without the need for the test sample to be sent to a lab for processing by a trained technician. The test can be used alongside current testing methods in areas where laboratory access is limited or non-existent.
Additionally, Therma has negotiated terms in the co-development agreement for the right to invest in a COVID-19 therapeutic drug development program currently underway by the same management team as Orpheus' and under a separate corporate entity. Therma's participation will be by way of an equity investment to be announced at the time of investment.
Mr. Rob Fia, CEO of Therma Bright commented, "We are excited to have entered into this co-development arrangement with the Orpheus' team and its vast network of academic and clinical institution collaborators. Therma is committed to an expedited path to regulatory approval of the CoviSafe™ test by providing its expertise in medical device engineering, compliance, and regulatory affairs."
Dr. Saeid Babaei, Chairman & CEO of Orpheus Medica commented, "Orpheus can leverage the partnership with Therma by using its internal core capabilities including research and development, and clinical trial operations and validation to improve the speed, accuracy, accessibility, and affordability of COVID-19 testing, a major step in helping to prevent the spread of COVID-19. We have assembled a number of key collaborations with various industry and academic entities to innovate and accelerate our developmental timelines in addition to engaging with our trusted and established suppliers, manufacturers and service providers."
About Therma Bright Inc.
Therma Bright is a progressive medical device technology company focused on providing consumers and medical professionals with quality medical devices that address their medical and healthcare needs. The Company's initial breakthrough proprietary technology delivers effective, non-invasive and pain-free skincare. Therma Bright received a Class II medical device status from the FDA for its platform technology that is indicated for the relief of the pain, itch, and inflammation of a variety of insect bites or stings. The Company received clearance for the above claims from the US FDA in 1997.
Therma Bright Inc. trades on the TSXV (TSXV: THRM). For more information visit: www.thermabright.com and www.coldsores.com.
About Orpheus Medica Inc.
Orpheus Medica is a fully integrated research-driven Canadian biotech company focused on the development and commercialization of innovative diagnostic and therapeutics for unmet medical needs. Orpheus, with its fully integrated R&D infrastructure, provides strategic partners and collaborators access to its proven and proprietary discovery and development of novel biopharmaceutical products. Our team has over 15 years of proven and validated computational capabilities for analysis and optimization of antibodies and peptides as well as small molecules.
For further information, please contact:
Therma Bright Rob Fia, CEO rfia@thermabright.com
Orpheus Medica Saeid Babaei, Chairman & CEO sbabaei@orpheusmed.com
============
Toronto, Ontario--(Newsfile Corp. - September 3, 2020) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), a progressive medical device technology company, is pleased to announce that its co-development partner, Orpheus Medica Inc. ("Orpheus") has identified a series of polypeptides for the screening and detection of the virus (SARS-CoV-2) causing COVID-19.
The research carried out by Orpheus and its academic collaborators has resulted in several high-quality polypeptides that recognize the COVID-19 virus with clear distinction from other coronavirus types such as SARS or MERS. These biological molecules will form the basis of the CoviSafe™ that is being developed to screen and detect the proteins of the virus rather than its genetic material. Therma and Orpheus expect to provide additional test formats where the user can test and differentiate between COVID-19 and seasonal flu symptoms.
Recently, Health Canada announced that it will be taking applications for home testing devices for screening purposes for COVID-19.
See National Post: https://nationalpost.com/pmn/health-pmn/health-canada-changes-course-on-covid-testing-at-home
CoviSafe™ is a screening test designed to monitor large populations of healthy individuals that are asymptomatic for the COVID-19 illness. CoviSafe™ can also be used as a diagnostic test to investigate individuals with COVID-like symptoms. CoviSafe™ will have a number of quality control features to avoid misuse or misinterpretation of home-based test results, which address a number of Health Canada's concerns as outlined in the article by the National Post. Therma and Orpheus will be carrying out field evaluation testing to determine test performance in different settings. The goal is to provide our solution for routine and widespread testing at schools, workplaces, sporting events or at home.
Dr. Saeid Babaei, Chairman & CEO of Orpheus commented: "We are excited to identify and validate the first series of our polypeptides in collaboration with our academic partners in a timely fashion. The detection molecules discovered to-date have already been validated in a COVID-19 model in the laboratory. Our plan is to further validate these results on the device platform as the next step in coming weeks."
Mr. Rob Fia, CEO of Therma Bright, commented: "We believe that CoviSafe™ can be developed as a low cost, saliva-based solution, that produces fast and accurate results for use at point of care or home, school, business or sporting event applications. We are excited for the potential to incorporate features that identify whether someone has COVID-19 or the seasonal flu. Therma and Orpheus believe this goal is the game changer that the world is looking for to get back to normalcy."